About Tepezza Lawsuit
Tepezza (teprotumumab) was approved by the FDA in 2020 to treat thyroid eye disease (TED), a rare but serious autoimmune condition. However, multiple patients reported sudden and permanent hearing loss after infusion treatments. Horizon Therapeutics failed to adequately warn about this significant adverse effect, leaving patients and doctors unprepared for the serious ototoxic (hearing damage) effects.
Post-marketing reports documented that Tepezza infusions could cause sensorineural hearing loss, tinnitus, and balance disorders. Some patients experienced permanent hearing loss requiring hearing aids after their Tepezza treatment. The severity of hearing loss in some cases was so significant that patients could no longer work or function normally.
After hearing loss reports accumulated, the FDA added a warning to Tepezza's label, but the initial labeling was inadequate. If you received Tepezza infusions for thyroid eye disease and subsequently suffered sudden hearing loss or hearing impairment, you may have a significant claim against Horizon Therapeutics.